The U.S. Department of Justice announced two settlements with pharmaceutical companies Thursday for a total of more than $100 million in penalties under the False Claims Act and the Food, Drug and Cosmetic Act. The announcements came two days after the department reached a $520 million settlement with AstraZeneca for similar violations involving unapproved uses of drugs.

In one settlement, two Johnson & Johnson subsidiaries, Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., will pay more than $81 million for the off-label promotion of the epilepsy drug Topamax, according to a DOJ statement.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]